

David Hillus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9774378/publications.pdf>

Version: 2024-02-01

10
papers

1,198
citations

1040056

9
h-index

1372567

10
g-index

16
all docs

16
docs citations

16
times ranked

2278
citing authors

#	ARTICLE	IF	CITATIONS
1	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. <i>Nature Medicine</i> , 2022, 28, 477-480.	30.7	342
2	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25.	28.9	122
3	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. <i>Emerging Infectious Diseases</i> , 2022, 28, 1050-1052.	4.3	11
4	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	4.8	52
5	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e7-1520.e10.	6.0	13
6	A time-resolved proteomic and prognostic map of COVID-19. <i>Cell Systems</i> , 2021, 12, 780-794.e7.	6.2	125
7	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2169-2173.	4.3	17
8	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265.	10.7	279
9	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. <i>Emerging Infectious Diseases</i> , 2021, 27, 2174-2178.	4.3	67
10	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, e104-e105.	10.7	65